FIBROMAX (FIBROSIS, ACTIVITY, STEATO, ASH AND NASH OF LIVER)

FIBROMAX (FIBROSIS, ACTIVITY, STEATO, ASH AND NASH OF LIVER) is a specialized non-invasive diagnostic biochemical test panel designed to evaluate the condition of the liver. FibroMax combines multiple blood serum markers into patented algorithms to provide quantitative assessments of liver injury, including fibrosis, necroinflammatory activity, hepatic steatosis (fatty liver), alcoholic steatohepatitis (ASH), and non-alcoholic steatohepatitis (NASH).

Measurement of these specific biomarker panels provides direct clinical insight into chronic liver diseases without the need for an immediate invasive biopsy. Because early identification of liver damage supports timely dietary, lifestyle, and medical intervention, specialized biochemical testing supplies essential clinical data for hepatology, gastroenterology, internal medicine, and metabolic evaluations.

The test requires a blood specimen collected by a qualified person using standard containers, followed by precise analysis using automated laboratory immunoassay and biochemical techniques. Results must always be interpreted in conjunction with the patient's clinical presentation, imaging studies, and medical history.

Benefits of FIBROMAX Testing

• Provides a comprehensive non-invasive assessment of liver health.
• Evaluates liver fibrosis stages and necroinflammatory activity.
• Assists clinicians in detecting hepatic steatosis (fatty liver).
• Aids in identifying alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH).
• Supports tracking of specialized therapeutic and lifestyle care plans.
• Complements liver imaging, ultrasound, and histological evaluations.
• Utilizes precise laboratory biomarker algorithms for reliable results.
• Assists specialists in determining appropriate medical and dietary management strategies.
• Provides dependable turnaround times to support specialized clinical care.
• Utilizes standard venous blood collection procedures.

Clinical Indications and Applications

Liver Health Screening: The primary clinical indication is evaluating patients presenting with risk factors for chronic liver disease, metabolic syndrome, obesity, diabetes, or chronic alcohol use.

Clinical Assessment: The test is utilized when screening for liver fibrosis and steatohepatitis in specialized clinical settings.

Why Doctors Recommend This Test

Hepatologists, gastroenterologists, endocrinologists, and physicians recommend this test when investigating chronic liver conditions or monitoring disease progression without routine biopsies. It delivers essential quantitative data required to guide safe clinical intervention.

Following proper blood collection guidelines will ensure a smooth and efficient testing procedure.

What Happens During The Procedure?

The collection procedure involves obtaining a blood specimen drawn from a vein by a qualified phlebotomist using a clean, standard collection container provided by the healthcare facility under appropriate supervision protocols.

Once obtained, the sample is tested in the laboratory using advanced biochemical and immunoassay analyzers to process the marker panel. The procedure takes only a few minutes.

Normal Reporting Time

The report for the FIBROMAX (FIBROSIS, ACTIVITY, STEATO, ASH AND NASH OF LIVER) test is generally available within 24 to 48 hours due to standard laboratory processing times. Results must be reviewed promptly with the referring physician or specialist.

Who Should Consider This Test?

• Patients with metabolic syndrome, diabetes, or obesity evaluated for fatty liver disease.
• Individuals investigated for chronic liver injury, fibrosis, or steatohepatitis as directed by a clinician.

Understanding Test Results

Test results provide quantitative scores and indices for fibrosis, activity, steatosis, ASH, and NASH, evaluated against established laboratory algorithms and validation standards.

Low Indices: Low scores indicate minimal or absent liver damage, fibrosis, or fat accumulation.

Elevated Indices: Elevated scores indicate significant liver fibrosis, active inflammation, or steatohepatitis requiring specialized medical management.

Clinical Limitations

FibroMax indices are calculated algorithmic models that must be interpreted alongside clinical context, patient history, and secondary diagnostic findings.

Important Safety Information

Severe liver symptoms or acute medical conditions require immediate medical attention. Patients must consult their healthcare provider or specialist to interpret panel findings.